PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Symptom | C0153690|bone metastases |
| Sentences | 122 |
| PubMedID- 22166044 | Therefore, prostate cancer survivors with bone metastases suffer not only from the treatment-related side effects common to survivors with localised disease, but also from significant physical and psychological issues associated with bone metastatic disease and its treatment. |
| PubMedID- 22341993 | A randomized, dose-response, multicenter phase ii study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. |
| PubMedID- 22078585 | Re: denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. |
| PubMedID- 19901958 | Zoledronic acid is standard of care for castration-resistant prostate cancer with bone metastases as it reduces the risk for skeletal-related events. |
| PubMedID- 23578501 | Objective: to construct a classification and regression tree (cart) to predict the occurrences of bone metastases in patients with newly diagnosed prostate cancer so as to reduce unnecessary bone scans. |
| PubMedID- 23374004 | A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (ebrt) among metastatic castrate resistance prostate cancer (mcrpc) patients with painful bone metastases. |
| PubMedID- 23903557 | Guidelines should include f-fluoride pet/ct and c-choline or f-choline pet/ct as alternatives for tc-bs for the detection of bone metastases in patients with prostate cancer. |
| PubMedID- 19588206 | In this study, we have evaluated the potential role of fch-pet/ct for the assessment of bone metastases in patients with prostate cancer. |
| PubMedID- 21048940 | Breast or prostate cancer patients coping with bone metastases experience intractable pain, which affects their quality of life. |
| PubMedID- 23864249 | We conducted a prospective study in recruiting 137 prostate cancer patients with bone metastases from 2008 to 2010. |
| PubMedID- 26447381 | Immunoscintigraphy with 99mtc-nimotuzumab for planning immunotherapy in patients with bone metastases due to prostate cancer. |
| PubMedID- 22126137 | Recently, zoledronic acid was proven to be effective in preventing skeletal-related events for prostate cancer patients with bone metastases. |
| PubMedID- 24156932 | Factors that predict the development of bone metastases due to prostate cancer: recommendations for follow-up and therapeutic options. |
| PubMedID- 24802278 | The aim of this paper was to evaluate currently available treatment options in the prevention and management of sres and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. |
| PubMedID- 23096187 | Objective: the purpose of this study was to evaluate the accuracy of whole-body diffusion-weighted mri (dwi) and (18)f-naf pet/ct for detection of bone metastases in patients with high-risk prostate cancer. |
| PubMedID- 25723740 | Purpose/objectives:: radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases. |
| PubMedID- 23871417 | Background: the endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer. |
| PubMedID- 24250030 | prostate cancer with lytic bone metastases: 18f-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy. |
| PubMedID- 21992720 | Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. |
| PubMedID- 26451465 | In the third study denosumab was non-inferior to zoledronic acid but was not superior to zoledronic acid in solid tumors except breast and prostate cancer with bone metastases. |
| PubMedID- 24630685 | Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the zometa european study (zeus). |
| PubMedID- 25224665 | Purpose: the aim of this study was to evaluate the efficacy and safety of zoledronic acid (za) in the combination of docetaxel-based chemotherapy for castration-resistant prostate cancer with bone metastases. |
| PubMedID- 24595005 | Background: bone metastases in prostate cancer (cap) result in cap-related morbidity/mortality. |
| PubMedID- 25005491 | Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. |
| PubMedID- 22110981 | In their study, zoledronic acid at 4 mg or 8 mg given every 3 weeks reduced skeletal-related events (defined as pathologic bone fractures (vertebral or nonvertebral), spinal cord compression, bone surgery, radiation therapy to bone, or a change of antineoplastic therapy to treat bone pain) and increased the median time to first skeletal-related event in prostate cancer patients with bone metastases. |
| PubMedID- 24505298 | A flare-up phenomenon could be proposed, as described on several occasions on – and particularly nsclc patients treated with erlotinib presenting an osteoblastic bone flare-up response mimicking disease progression. |
| PubMedID- 24113758 | A 67-year-old man with castration-resistant prostate cancer associated with multiple bone metastases had been treated with zoledronic acid and docetaxel. |
| PubMedID- 23302484 | The building and validation of a model to predict the bone metastases of patients with newly diagnosed prostate cancer. |
| PubMedID- 21336561 | Optimal management of bone metastases in prostate cancer. |
| PubMedID- 23273271 | The bone metastases of prostate cancer are usually radiologically osteoblastic. |
| PubMedID- 23301832 | The bone metastases of prostate cancer cells are predominantly associated with the formation of osteoblastic lesions (bone formation), whereas bone metastases of breast cancer cells are generally related with the formation of osteolytic lesions (bone destruction). |
| PubMedID- 25952970 | Methods: we sequenced the mitochondrial genome in 10 prostate cancer patients with bone metastases enrolled in a rapid autopsy program. |
| PubMedID- 23828554 | This retrospective study aimed to examine these relationships in prostate cancer patients with bone metastases. |
| PubMedID- 23086758 | prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. |
| PubMedID- 24503416 | This review analyzes the data supporting the use of all presently available therapeutic approaches for the management of pain, skeletal events, and survival in castration-resistant prostate cancer patients with bone metastases. |
| PubMedID- 23041906 | The du145 and pc-3 lines were derived from brain and bone metastases of prostate cancer, whereas the ar(+), psma(+) lncap cell line was derived from a lymph node metastasis. |
| PubMedID- 22579776 | Serum sclerostin levels in paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. |
| PubMedID- 22748612 | Objective: to evaluate a cohort of united states-based urology practices for patterns related to screening, diagnosis, and treatment of bone metastases in men with castration-resistant prostate cancer. |
| PubMedID- 21894431 | We had previously reported on advanced prostate cancer (pca) patients with multiple distant bone metastases in whom serum alpha2m levels were markedly decreased (alpha2m deficiency). |
| PubMedID- 26262831 | Management of bone metastases in prostate cancer: a review. |
| PubMedID- 21550141 | Our results show that patients of prostate cancer with bone metastases have increased bone mineral density (bmd) in the pelvis and trunk, possibly because of a predominance of osteoblastic over osteolytic metastases demonstrated by (99m)tc mdp bone scan. |
| PubMedID- 22570568 | Similarly, 1- and 3-year cumulative survival in prostate cancer patients diagnosed with bone metastases was 47% and approximately 9%,14 respectively. |
| PubMedID- 22402111 | Objective evaluation of bone metastases in prostate cancer: to what end. |
| PubMedID- 25407275 | bone metastases in prostate cancer: which scan. |
| PubMedID- 25670024 | In the periphery, cancer cell lines including breast and prostate cancers associated with bone metastases also exhibit increased secretion of glutamate that contributes to the disruption of normal bone homeostasis and cibp21. |
| PubMedID- 21190792 | Background: clinical data have limited validity for predicting the survival of prostate cancer (pca) patients with bone metastases. |
| PubMedID- 21080800 | Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer, but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting. |
| PubMedID- 24212441 | Targeted alpha-particle therapy of bone metastases in prostate cancer. |
| PubMedID- 23791392 | A multicenter phase 1 study of emd 525797 (di17e6), a novel humanized monoclonal antibody targeting alphav integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. |
| PubMedID- 21342722 | Comparison of bone scintigraphy and 18f-fdg pet-ct in a prostate cancer patient with osteolytic bone metastases. |